Nyctophobia: understanding and overcoming the fear of the dark

Nyctophobia refers to an intense and persistent fear of darkness. Understanding its clinical definition and etymology helps distinguish it from an ordinary fear from the outset.

Clinical definition and diagnostic criteria

According to the DSM-5 diagnostic criteria[1], nyctophobia is classified among specific phobias: it is characterized by a persistent, excessive and disproportionate fear of darkness, almost invariably triggering an anxiety response upon exposure. Avoidance is systematic, and the disorder causes measurable functional impairment: disrupted sleep, reduced independence and an affected social life.

Fear of the dark is normal between ages 3 and 8 and is linked to children's cognitive development. It becomes a phobic disorder when it persists beyond this period, intensifies or interferes with everyday life. Diagnosis is based on these formal criteria, not on the subjective intensity of the fear experienced.

Etymology and synonyms

The term comes from the Greek nyktos (night) and phobos (fear). Several clinical synonyms coexist: achluophobia, scotophobia, lygophobia and noctiphobia. These terms refer to the same disorder with minor etymological differences, but no diagnostic distinction separates them. Nyctalophobia, which is sometimes confused with it, refers to difficulty seeing in low light, not to a fear. In clinical practice, nyctophobia and scotophobia are the most commonly used terms.

Nyctophobia is not rare. According to data on the prevalence of specific phobias[2], 5 to 15% of the general population experiences a specific phobia during their lifetime. Across all phobias, the sex ratio is more than 2 women for every 1 man.

Peak onset occurs between ages 5 and 9, a period when the imagination is particularly active and the distinction between reality and fantasy remains blurred. Fear of the dark at this age is often developmental. It becomes concerning when it persists, worsens or prevents the child from functioning normally.

In adults, nyctophobia is often an untreated childhood phobia that has become chronic. It can also develop following a traumatic experience in adulthood. Contrary to popular belief, phobias do not disappear spontaneously over the years: situational phobias, which include nyctophobia, may even increase with age. This disorder affects all age groups, including older people.

Three categories of symptoms coexist: physical, emotional and behavioral. Their intensity varies depending on the severity of the disorder and the person's profile.

Physical symptoms

In darkness, the autonomic nervous system triggers a fight-or-flight response, resulting in immediate physical manifestations:

• Palpitations and increased heart rate
• Excessive sweating
• Trembling or shivering
• Breathing difficulties, a feeling of tightness
• Chest pain or tightness
• Nausea, gastrointestinal disturbances

These symptoms are not “all in the mind”: they reflect genuine physiological activation, identical to that observed in other anxiety disorders. They appear rapidly, sometimes almost immediately as the light dims.

Emotional and behavioral symptoms

Anticipatory anxiety is often the first sign: the person experiences anxiety even before being exposed to darkness, simply by imagining the situation. Panic then occurs during actual exposure, accompanied by a sense of imminent danger that is difficult to reason away.

Behaviorally, avoidance gradually develops: refusing to sleep without a light, avoiding dark places (basements, unlit corridors, cinemas), and rituals of checking light sources before bed. These strategies provide short-term relief but reinforce the phobia over time by preventing any habituation. Independence decreases and quality of life deteriorates.

No single cause explains nyctophobia. The current model is multifactorial: several factors interact, and their combination varies from person to person.

Developmental factors play a central role. Between ages 3 and 5, fear of the dark is a normal stage: the imagination is highly active, and children still struggle to distinguish reality from fantasy. This fear becomes problematic if it persists beyond ages 8–9 or intensifies instead of fading. A professional assessment is then necessary.

Traumatic experiences are another common trigger. A negative experience in darkness (an accident, an assault, a panic episode) can condition a lasting fear response, even if the event occurred long ago.

Social learning also plays a role. A child who regularly observes a parent expressing an intense fear of darkness may internalize this reaction as normal or as a sign of danger, without ever having had a direct traumatic experience.

Finally, certain temperamental predispositions increase vulnerability: high trait anxiety, heightened sensitivity to stimuli, or a family history of anxiety disorders. These genetic and biological factors do not determine the onset of a phobia on their own, but they create a predisposition.

Nyctophobia is not limited to nighttime discomfort. Its functional consequences extend throughout everyday life.

Sleep disturbances are the most immediate effects: difficulty falling asleep, frequent nighttime awakenings and unrefreshing sleep. The resulting daytime fatigue affects concentration, mood and academic or work performance. Chronic irritability can strain close relationships.

In children, dependence on parents is prolonged: needing an adult present to fall asleep, refusing to stay alone in a dark room, and separation anxiety. These behaviors, understandable in the short term, can hinder the development of independence and affect socialization.

In adults, the limitations are broader. Some avoid trips involving nights away from home, nighttime outings, or certain work environments. Social isolation gradually develops, sometimes accompanied by shame that delays seeking help. Untreated nyctophobia tends to become entrenched, rather than disappear.

Several therapeutic approaches are validated. Psychotherapies, particularly CBT, are the first-line treatment. Medication has a very limited role in isolated specific phobias, such as entomophobia.

Cognitive behavioural therapies (CBT)

CBT is recommended as a first-line treatment for anxiety disorders by HAS, NICE and WHO. Its effectiveness in specific phobias is documented by more than 1,000 randomised controlled trials, with an improvement rate of 60 to 70%[3].

The mechanism relies on two complementary approaches. On one hand, cognitive restructuring: identifying and questioning automatic catastrophic thoughts (“something will happen to me in the dark”), testing them against reality and developing more balanced alternatives. On the other, behavioural work: gradually reducing avoidance and safety rituals.

CBT for a specific phobia generally lasts 12 to 20 sessions over 3 to 6 months. Exercises practised between sessions are essential: this is where change is consolidated.

For mental health professionals wishing to incorporate gradual exposure into their practice, C2Care offers virtual reality environments controlled in real time by the practitioner. More than 250 exposure situations are available, adaptable to the patient's pace and reactions, within a reproducible and controlled setting.

Gradual exposure and desensitisation

Graded exposure is at the heart of phobia treatment. The principle is to confront the person with darkness gradually, starting with situations that cause little anxiety (a dimly lit room, subdued lighting) and progressing towards complete darkness. Exposure duration increases at each stage.

The aim is habituation: through repeated exposures without negative consequences, the brain revises its assessment of the threat and anxiety decreases. This exposure can be carried out in imagination, in real-life situations (in vivo), or through virtual reality exposure therapy environments that provide an adjustable and reproducible setting, particularly useful for situations that are difficult to recreate in a consulting room.

Complementary approaches and limitations of medication

Relaxation, controlled breathing and mindfulness techniques can complement CBT. They help regulate physiological arousal during exposure, but are not sufficient on their own to treat an established phobia.

Regarding medication, the situation is clear: there is no validated drug treatment for isolated specific phobias. Benzodiazepines may be prescribed occasionally in acute situations, without any long-term beneficial effect. Antidepressants (SRIs) are indicated only in cases of confirmed comorbid depression. Psychotherapy remains the standard approach.